Seeking Alpha

GlaxoSmithKline (GSK -0.2%) says regulatory approval for its H5N1 bird flu vaccine has been...

GlaxoSmithKline (GSK -0.2%) says regulatory approval for its H5N1 bird flu vaccine has been delayed. The company blamed the setback on a "recently rectified administrative matter" and says it is working closely with the FDA to ensure the review will be wrapped up as soon as possible. 
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs